Holen Sie sich die Stockscreener-App
87.68
0.06%
0.05
Schlusskurs vom Vortag:
$87.63
Offen:
$87.64
24-Stunden-Volumen:
310.27K
Relative Volume:
1.81
Marktkapitalisierung:
$587.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.99M
KGV:
-42.43
EPS:
-2.0665
Netto-Cashflow:
$-10.01M
1W Leistung:
+29.95%
1M Leistung:
+40.02%
6M Leistung:
+27.50%
1J Leistung:
+150.44%
1-Tages-Spanne:
$85.70
$92.25
1-Wochen-Bereich:
$66.83
$94.83
52-Wochen-Spanne:
$29.18
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Firmenname
Monopar Therapeutics Inc
Sektor
Branche
Telefon
(847) 388-0349
Adresse
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
87.68 | 587.37M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-11-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-09-09 | Eingeleitet | BTIG Research | Buy |
| 2025-09-03 | Eingeleitet | Oppenheimer | Outperform |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-08-26 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-19 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Piper Sandler | Overweight |
| 2024-10-11 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-01-28 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
Enterprise value to EBITDA forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Enterprise value to revenue forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Enterprise value to revenue forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Price to sales forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Price to earnings forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Monopar plans mid-2026 NDA filing for Wilson disease drug - Investing.com UK
MNPR Forecast — Price Target — Prediction for 2027 - TradingView
Monopar Therapeutics Inc Actuals & Estimates (NASDAQ:MNPR) - TradingView
Monopar Highlights Positive Phase 3 Wilson Disease Data - TipRanks
Monopar Therapeutics (MNPR) to Present New Data on ALXN1840 at E - GuruFocus
Monopar Presents Phase 3 FoCus Data Showing Neurologic and Global Benefit with ALXN1840 - TradingView
Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson Disease - The Manila Times
ALXN1840 Phase 3 data back NDA plan for Wilson disease, Monopar (NASDAQ: MNPR) - Stock Titan
Monopar’s Wilson disease drug shows stronger neurologic gains in Phase 3 - Stock Titan
Monopar Therapeutics Inc Actuals & Estimates (LS:A40JML) - TradingView
Monopar Therapeutics Inc Actuals & Estimates (DUS:1IY0) - TradingView
A40JML Forecast — Price Target — Prediction for 2027 - TradingView
1IY0 Forecast — Price Target — Prediction for 2027 - TradingView
NDA submission progress for ALXN1840 in Wilson disease sends Monopar Therapeutics stock up 7.61% - Traders Union
Monopar Therapeutics Inc Cash Flow – DUS:1IY0 - TradingView
Monopar Therapeutics Inc (MNPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Near-term momentum pushes Monopar Therapeutics stock up 7.19% - Traders Union
Monopar Therapeutics shareholders approve all proposals at annual meeting - Investing.com
Monopar Shareholders Approve Directors, Pay and Incentive Plan - TipRanks
Monopar Therapeutics 8-K Filing: Annual Meeting Results, Stock Incentive Plan Approval, and Key SEC Information - Minichart
Monopar (NASDAQ: MNPR) meeting backs board, pay and 2026 plan - Stock Titan
Free cash flow per share of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Upcoming Virtual Meeting for MNPR Set for June 23 - GuruFocus
Strong demand pushes Monopar Therapeutics stock higher in an extended rally - Traders Union
Monopar Therapeutics Inc Balance Sheet – DUS:1IY0 - TradingView
Why (MNPR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Operating income of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics stock gains 3.15% as price finishes near session high - Traders Union
Basic earnings per share (basic EPS) of Monopar Therapeutics Inc – DUS:1IY0 - TradingView
Monopar Therapeutics StockThursday chart and volatility snapshot - Ad-hoc-news.de
Monopar Therapeutics Inc (MNPR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Monopar Therapeutics Inc (MNPR) Institutional Confidence - TradingKey
Monopar Therapeutics Inc (MNPR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Monopar Therapeutics Inc (MNPR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Monopar Therapeutics Inc (MNPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Why is Monopar Therapeutics stock up today? - Traders Union
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade - MSN
Monopar Therapeutics Inc (MNPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monopar Therapeutics Inc (MNPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Monopar Therapeutics stock price forecast: $66.1636 resistance in focus as MNPR climbs 3.12% - Traders Union
Monopar Therapeutics Q1 2026 Earnings: Smaller-than-Expected Loss as EPS Surprises PositivelyRevenue Report - newsline.com
Understanding Momentum Shifts in (MNPR) - Stock Traders Daily
Monopar Therapeutics (MNPR) Climbs Nearly 2%, Approaches Key Resistance at $63.64Inside Day Breakout - newsline.com
MNPR Stock Price and Chart — NASDAQ:MNPR - TradingView
Piper Sandler Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $101 - Moomoo
Finanzdaten der Monopar Therapeutics Inc-Aktie (MNPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):